Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01217671 | International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema | PHASE2 | COMPLETED | 168 | — | — | Dec 1, 2009 | Jun 1, 2015 | Nov 29, 2019 | 12 | Canada, Denmark +5 |
| Arm | Type | Description |
|---|---|---|
| Alpha-1 Antitrypsin | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Kamada AAT for inhalation | BIOLOGICAL | Alpha-1 Antitrypsin (AAT) |
| Placebo | OTHER | Placebo |
Principal Inclusion Criteria: * Diagnosis of emphysema confirmed by CT scan. If a report of past CT scan is not available at site documenting then a CT scan is to be performed at screening * Male or female patients at least 18 years of age. * Able and willing to sign an informed consent. * Patient ...